Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 10/20 | 0.39 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | MC3R | P41968 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15038325 | 0.81 | KDM4E (0.42) | CYP19A1FDPSBTN3A1PDE3AKDM4E | |
| SCHEMBL10704341 | 0.72 | L3MBTL1 (0.57) | FDPSNAPRT | |
| SCHEMBL16231362 | 0.70 | CYP19A1 (0.48) | CYP19A1KDM4ENAPRTHCAR2BAZ2B | |
| SCHEMBL9474833 | 0.70 | CYP19A1 (0.48) | CYP19A1KDM4ENAPRTHCAR2BAZ2B | |
| SCHEMBL3293497 | 0.69 | CYP19A1 (0.47) | CYP19A1KDM4ENAPRTHCAR2BAZ2B | |
| SCHEMBL13746036 | 0.67 | FDPS (0.53) | CYP19A1FDPSBTN3A1PDE3A | |
| SCHEMBL5720338 | 0.66 | CYP19A1 (0.44) | CYP19A1KDM4ENAPRTHCAR2BAZ2B | |
| SCHEMBL8337291 | 0.66 | KDM4E (0.41) | FDPSKDM4ENAPRTHCAR2BAZ2B | |
| SCHEMBL31256061 | 0.64 | CYP19A1 (0.42) | CYP19A1KDM4ENAPRTHCAR2BAZ2B | |
| SCHEMBL179284 | 0.64 | CYP19A1 (0.42) | CYP19A1KDM4ENAPRTHCAR2BAZ2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140339098-A1 | PROCESS AND CATALYST FOR THE ELECTROCHEMICAL REDUCTION OF CARBON DIOXIDE | SOLVAY SA (BE) | 2014-11-20 | — | — | US | disclosed |
| US-20140339098-A1 | PROCESS AND CATALYST FOR THE ELECTROCHEMICAL REDUCTION OF CARBON DIOXIDE | SOLVAY SA (BE) | 2014-11-20 | — | — | US | disclosed |
| WO-2013087792-A2 | PROCESS AND CATALYST FOR THE ELECTROCHEMICAL REDUCTION OF CARBON DIOXIDE | SOLVAY SA (BE) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140339098-A1 | PROCESS AND CATALYST FOR THE ELECTROCHEMICAL REDUCTION OF CARBON DIOXIDE | BPGM, CA4, CA6 | CYP19A1 763/4885FDPS 259/4885BTN3A1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.